The study found that trusts with more pure thoracic surgeons saw a significant increase in lung cancer resection rates. In 2009, the overall resection rate rose by 46% due to increased investment in thoracic surgical expertise.
Research reveals disparities in trial populations reflecting U.S. demographics, with women and older patients under-enrolled. Minority groups also show significant underrepresentation, highlighting concerns about toxicity and treatment efficacy.
A new PET imaging technique using [11C]erlotinib may help doctors identify lung cancers that respond well to tyrosine kinase inhibitors (TKIs), enabling personalized therapy. The test showed significantly higher tracer uptake in tumors with activating EGFR mutations, indicating a potential non-invasive predictive marker.
Research reveals that lung adenocarcinomas in never-smokers exhibit greater genome instability and altered genetic patterns compared to those in smokers. The findings suggest distinct molecular mechanisms driving the development of lung cancer in never-smokers, potentially requiring unique treatments.
A new study reveals that ALK rearrangement affects nearly 10% of lung cancer patients, while MET amplification occurs in another 4.1%. This could lead to targeted therapy options like crizotinib for these patients.
The EURTAC Phase III study found that erlotinib nearly doubled progression-free survival compared to chemotherapy, with a better tolerability profile for Western patients with NSCLC and EGFR activating mutations. The response rate to erlotinib was 54.5%, significantly higher than the 10.5% response rate to chemotherapy.
Research found that high EGFR expression is a predictor of improved survival in advanced non-small cell lung cancer patients treated with cetuximab and chemotherapy. Patients with high tumor EGFR expression averaged 12 months of overall survival, compared to 9.6 months for those without high expression.
The International Association for the Study of Lung Cancer (IASLC) welcomed the publication of positive results from the National Lung Screening Trial, which showed a 20% reduction in lung cancer deaths and a 7% decrease in all-cause mortality among heavy smokers screened with low-dose spiral computed tomography. The trial followed ove...
Researchers found Asian non-small cell lung cancer patients survived longer than Caucasians regardless of the number of chemotherapy drugs given, with improved survival rates after targeted therapies were introduced in the early 2000s.
Five advocacy organizations from India, Australia and the US have been granted travel awards by IASLC to attend the 14th World Conference on Lung Cancer in Amsterdam. The winners will enjoy free registration, accommodation and travel expenses, as well as free IASLC affiliate membership.
Researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic effect on all mesothelioma cells. The study suggests using mTOR inhibitors as a novel anti-mesothelioma strategy, particularly in combination with chemotherapy.
A recent study published in the Journal of Thoracic Oncology found that soy isoflavones can sensitize cancer cells to radiation, increasing killing efficiency while protecting normal lung tissue from damage. Researchers used a soy mixture consisting of genistein, daidzein and glycitein to demonstrate this effect.
The new TNM 7 lung cancer staging system better predicts local or regional recurrence after surgery, according to a study published in the Journal of Thoracic Oncology. The updated system improved accuracy for predicting disease recurrence among patients with non-small cell lung cancer.
Small-screen detected lung cancers with maxSUV of 2.0 or smaller nodules than 10mm have low risk of nodal metastases, suggesting some patients can avoid invasive procedures. This reduces operating time and morbidity associated with lymph node dissection.
Researchers suggest that quitting smoking suddenly may be an early symptom of lung cancer. A study found that 48% of patients with lung cancer had quit before diagnosis, most without noticing any symptoms.
Research suggests that high levels of circulating DNA, specifically human telomerase reverse transcriptase (hTERT), can indicate a faster progression of lung cancer and lower overall survival. Patients with lower hTERT levels had improved time to progression and higher overall survival rates compared to those with higher levels.
A new international multidisciplinary classification of lung adenocarcinoma has been published by three top lung associations. The classification takes a comprehensive approach, incorporating advances in genetics, clinical information, and molecular studies to improve diagnosis and treatment.
A China Medical University study shows a 10.9-fold increased risk of lung cancer among people with tuberculosis compared to those without the disease. The study followed over 1 million patients and found a mortality rate of 51.1 per 10,000 person-years in the tuberculosis group, nearly six times that of non-tuberculosis patients.
Researchers found lung adenocarcinomas in young patients with pediatric cancers, displaying similar gene mutations as adult cases. The tumors may occur prior to chemotherapy treatment and are not always secondary malignancies.
The TRUST study found that erlotinib significantly increased survival for patients with previously treated advanced NSCLC. Certain patient groups, such as adenocarcinoma, women, and Asian ethnicity, showed greater tumor responses to EGFR TK inhibitors.
A new study published in the Journal of Thoracic Oncology found that approximately half of advanced non-small cell lung cancer patients received chemotherapy treatment, exceeding previous estimates. The retrospective analysis showed age and insurance type were associated with chemotherapy administration.
A study found that tumor budding is a distinct morphologic feature with biologic and prognostic significance in lung adenocarcinoma, significantly linked to aggressive disease characteristics. The presence of tumor budding was also associated with lower five-year survival rates.
A study published in Journal of Thoracic Oncology found that using the histoculture drug response assay to guide chemotherapy improves lung cancer survival and prognosis for patients who have undergone surgery. The use of adjuvant chemotherapy based on assay results showed a higher five-year survival rate compared to traditional treatm...
Research published in the Journal of Thoracic Oncology defines timeframes for declaring early stage lung cancer cured. Patients with stage IA NSCLC without vascular invasion can be considered cured after five years, while those with vascular invasion require longer follow-up until at least nine years.
A study of 342 early-stage lung cancer survivors found that nearly 60% experienced long-term dyspnea, with associated risk factors including reduced physical activity and depression. Targeting post-treatment rehabilitation strategies to improve breathlessness may be effective in improving outcomes.
A new method of tissue banking enables researchers to obtain high-quality RNA samples from lung tumor biopsies, increasing the number and type of tumors available for gene expression studies. This improves personalized medicine prospects for lung cancer patients.
Researchers found that administering nab-paclitaxel weekly resulted in a 48% response rate and less severe side effects compared to every-three-week dosing. The study showed improved anti-tumor activity and reduced nerve damage with the novel formulation.
Researchers analyzed surgical outcomes of non-small cell lung cancer patients over 30 years, finding improved survival rates with earlier stage diagnoses. The increase in patients diagnosed with early-stage adenocarcinoma is thought to contribute significantly to the favorable results.
A study published in the Journal of Thoracic Oncology found that high expression of CD24 is a negative independent prognostic factor for progression-free and cancer-specific survival in NSCLC. CD24-high expression was also associated with adenocarcinoma histology, higher risk of disease progression, and cancer-related death.
A new study published in the Journal of Thoracic Oncology found that sleeve lobectomy offers superior survival and better postoperative pulmonary function compared to pneumonectomy in selected patients. The study analyzed 210 lung cancer patients and reported lower mortality rates for those who underwent a sleeve lobectomy.
Research found no significant differences in tolerance and efficacy between elderly and non-elderly NSCLC patients receiving salvage targeted therapy or chemotherapy. Elderly patients showed comparable response rates, disease control, and survival times as younger patients.
Researchers found that lung cancer patients with optimistic attitudes had a six-month survival advantage over those with pessimistic attitudes. This study builds on existing research to investigate the effect of patient attitudes on outcomes in oncology populations.
Research found that split-course palliative radiotherapy reduced patients' symptoms by 52-84% and provided long-lasting relief in 58% of cases. Cancer survival rates were not adversely affected by a two-week break in treatment, demonstrating the regimen's potential as an optimal option for symptom management.
Research published in Journal of Thoracic Oncology investigates the effectiveness of surgery as a standalone treatment for stage I small cell lung cancer. The study found three- and five-year survival rates of 58.1% and 50.3%, respectively, for patients who underwent lobectomies without radiotherapy.
The new T classification is based on tumor size and has been validated as appropriate for pathologic findings. The study found significant differences in survival rates among revised T subsets, highlighting the importance of the revised TMN classification for lung cancer treatment planning.
Research analyzed over 100,000 patients with stage IV non-small cell lung cancer and found a modest but statistically significant improvement in one-year and two-year overall survival rates from 13.2% to 19.4% and 4.5% to 7.8%, respectively.
Research finds that lung cancer patients treated in public hospitals are more likely to have advanced stage cancer than those in private hospitals. The study highlights the need for an organized and timely approach to diagnosis and treatment to reduce health care disparities.
A study confirmed the efficacy of a simple questionnaire in identifying patients at high risk for lung cancer. The questionnaire, completed by over 1,000 patients, found almost half qualified as high risk and led to eight confirmed cases of lung cancer in five years.
A combination of PET/CT tests expedited diagnosis of lung cancer in a fast-tracked setting, demonstrating high sensitivity and accuracy. Researchers evaluated 114 patients and made accurate diagnoses for 92%, with malignancy detected in 84%. This approach allows for timely treatment initiation without delays.
Research links CHRNA3 and CHRNA5 genes to increased lung cancer risk in African Americans, despite lower smoking rates. The study, published in Journal of Thoracic Oncology, confirms a stronger association with lung cancer risk than nicotine dependence.
Research published in the Journal of Thoracic Oncology found that narrow-band imaging bronchoscopy increases lung cancer detection specificity and can serve as an alternative method. The study confirms its efficiency by comparing it with white light and auto-fluorescence imaging.
A pooled analysis of six clinical trials found that pretreatment quality of life can predict overall survival in patients with advanced stage NSCLC. Patients with low self-assessed quality of life have twice the risk of death as those with high scores.
A recent study published in the Journal of Thoracic Oncology found that tumor size and level of visceral pleura invasion significantly impact the survival of non-small cell lung cancer (NSCLC) patients. Researchers analyzed data from over 9,700 surgical resection cases and divided patients into nine groups based on tumor size and VPI.
Researchers found that combination therapies tailored to patient prognosis improved patient outcomes and increased five-year, disease-free survival rates. Prophylactic cranial irradiation was shown to significantly decrease the risk for brain metastases in NSCLC patients.
Recent studies at WCLC reveal that specific volatile organic compounds can help detect early stage lung cancer, while iloprost improves endobronchial dysplasia in former smokers. Researchers hope to develop a test examining exhaled breath for early detection of lung cancer using this information.
Studies presented at the WCLC confirm that targeted therapies have improved efficacy and prolonged progression-free survival time compared to chemotherapy. Patients with EGFR mutations who received gefitinib experienced longer progression-free survival and greater objective response rates, while erlotinib showed prolonged progression-f...
A study published in the Journal of Thoracic Oncology found a significant difference in the quality and type of lung cancer information available online in the US and Japan. The US websites were more likely to discuss standard treatment methods and had stricter ethical policies.
A study found that older age, lower education levels and longer smoking history are associated with a positive lung cancer diagnosis after an abnormal screening chest radiograph. A family history of lung cancer and suspicious masses also contribute to a true positive diagnosis.
Researchers found that exercise programs significantly reduced lung cancer symptoms in patients who completed the study, with no deterioration in functional capacity or muscle strength. The study suggests that community-based or shorter exercise programs may be more feasible for lung cancer patients to complete.
A study found that patients diagnosed with lung cancer through CT scans had a significantly higher 5-year survival rate (91.2%) compared to those diagnosed with x-rays (77.8%). The study suggests that early detection of the disease using CT scans improves patient prognosis.